Claro Advisors’s Rein Therapeutics RNTX Stock Holding History

Claro Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-83	Closed	-$5K	–	971
2018 Q4	$5K	Buy	+83	New	+$3.33K	﹤0.01%	800

Other funds holding RNTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JOYN Advisors Atlanta, Georgia $300M AUM 14.91% 1-Year Est. Return

Claro Advisors's RNTX Position: Q1 2019 in Review

Claro Advisors sold out of Rein Therapeutics (RNTX) in Q1 2019, closing a stake of 83 shares — an estimated $5K sold.

Claro Advisors first reported a position in RNTX in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q1 2019.

Claro Advisors reported no remaining Rein Therapeutics position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 83 Rein Therapeutics shares in Q1 2019, an estimated $5K.
Claro Advisors first reported a position in Rein Therapeutics in Q4 2018 and held it in 1 quarter.
Claro Advisors's Rein Therapeutics position peaked at $5K in Q4 2018.
23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.